Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, PT Famon Awal Bros Sedaya Tbk's average EBITDA Per Share Growth Rate was 44.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 34.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -3.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of PT Famon Awal Bros Sedaya Tbk was 34.90% per year. The lowest was -13.70% per year. And the median was -8.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PT Famon Awal Bros Sedaya Tbk 3-Year EBITDA Growth Rate Related Terms
ISX:PRAY vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, PT Famon Awal Bros Sedaya Tbk's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Famon Awal Bros Sedaya Tbk 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Famon Awal Bros Sedaya Tbk's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PT Famon Awal Bros Sedaya Tbk's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 34.90% mean?
PT Famon Awal Bros Sedaya Tbk (ISX:PRAY) has a 3-Year EBITDA Growth Rate of 34.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PT Famon Awal Bros Sedaya Tbk and its competitors. According to the industry distribution chart, PT Famon Awal Bros Sedaya Tbk ranks #96 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 18.3%.
Is PT Famon Awal Bros Sedaya Tbk's 3-Year EBITDA Growth Rate too high?
PT Famon Awal Bros Sedaya Tbk's current 3-Year EBITDA Growth Rate is 34.90%. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. PT Famon Awal Bros Sedaya Tbk's value of 34.90% is 252.5% above this industry median. Based on the distribution chart, PT Famon Awal Bros Sedaya Tbk ranks #96 out of 524 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, PT Famon Awal Bros Sedaya Tbk has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Famon Awal Bros Sedaya Tbk's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Famon Awal Bros Sedaya Tbk ranks #96 out of 524 companies for 3-Year EBITDA Growth Rate. This places PT Famon Awal Bros Sedaya Tbk in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 9.90. PT Famon Awal Bros Sedaya Tbk's value of 34.90% is 252.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Famon Awal Bros Sedaya Tbk's current 3-Year EBITDA Growth Rate of 34.90% is 252.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PT Famon Awal Bros Sedaya Tbk and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Famon Awal Bros Sedaya Tbk's current 3-Year EBITDA Growth Rate is 34.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Famon Awal Bros Sedaya Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Famon Awal Bros Sedaya Tbk (ISX:PRAY) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp903.34, compared to a current price of Rp750.00 — trading 17% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 34.90% and 252.5% above the Healthcare Providers & Services industry median of 9.90. PT Famon Awal Bros Sedaya Tbk's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PT Famon Awal Bros Sedaya Tbk (ISX:PRAY), the current 3-Year EBITDA Growth Rate is 34.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Famon Awal Bros Sedaya Tbk (ISX:PRAY) Overvalued in 2026?
Based on GuruFocus' analysis, PT Famon Awal Bros Sedaya Tbk stock appears to be undervalued.
The current stock price of Rp750.00 is trading 17% below its estimated GF Value™ of Rp903.34.
GuruFocus considers PT Famon Awal Bros Sedaya Tbk to be Modestly Undervalued.
Key valuation signals for ISX:PRAY:
3-Year EBITDA Growth Rate: 34.90%
GF Value™: Rp903.34 vs. price of Rp750.00 (17% below fair value)
Industry Position: 252.5% above the Healthcare Providers & Services median (#96 of 524)
No single metric tells the full story. See the ISX:PRAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Famon Awal Bros Sedaya Tbk operates as a hospital. The company7 provides comprehensive health services for Indonesians and foreign nationals (foreigners) and provides patient services with guarantees from companies, insurance, BPJS, and personal payments. Its hospital network has spread across different cities in Indonesia, including Jakarta, Bekasi, Tangerang, Semarang, Sukabumi, Makassar, Palangkaraya, and Pangkal Pinang. The services that it provides for patients include heart and blood vessel service centers, mother and child services, sports clinic & orthopedic services, cancer services, eye care centers & urology centers. The company's segments are Java; Kalimantan dan/ and Sulawesi; and Sumatera. It derives maximum revenue from Jawa.
90GF Score
Get the complete analysis for ISX:PRAY
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PRAY has been successfully added to your 
